alysts at 9:00 a.m. ET today. On the call, Michael Davin and Timothy Baker, the Company's Executive Vice President and Chief Financial Officer, will discuss Cynosure's financial results and provide a business overview. Those who wish to listen to the conference call webcast should visit the "Investor Relations
" section of the Company's website at www.cynosure.com
. The live call can also be accessed by dialing (877) 709-8155 or (201) 689-8881. If you are unable to listen to the live call, the webcast will be archived on the Company's website.
About CynosureCynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.
Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about future growth and commercialization or potential market acceptance of PicoSure, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities LitiPage: 1 2 3 4 5 6 7 Related medicine technology :1
. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles2
. Cynosure Announces Upcoming Conference Presentations3
. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock4
. Cynosure, Inc. Prices Public Offering of Class A Common Stock5
. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum6
. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 127
. Cynosure to Participate in Leerink Swann Global Healthcare Conference 20138
. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events9
. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.10
. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 201211
. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012